Nasal Immunization of Mice with Human Papillomavirus Type 16 Virus-Like Particles Elicits Neutralizing Antibodies in Mucosal Secretions
- 1 October 1998
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 72 (10) , 8220-8229
Abstract
To specifically induce a mucosal antibody response to purified human papillomavirus type 16 (HPV16) virus-like particles (VLP), we immunized female BALB/c mice orally, intranasally, and/or parenterally and evaluated cholera toxin (CT) as a mucosal adjuvant. Anti-HPV16 VLP immunoglobulin G (IgG) and IgA titers in serum, saliva, and genital secretions were measured by enzyme-linked immunosorbent assay (ELISA). Systemic immunizations alone induced HPV16 VLP-specific IgG in serum and, to a lesser extent, in genital secretions but no secretory IgA. Oral immunization, even in the presence of CT, was inefficient. However, three nasal immunizations with 5 μg of VLP given at weekly intervals to anesthetized mice induced high (>104) and long-lasting (>15 weeks) titers of anti-HPV16 VLP antibodies in all samples, including IgA and IgG in saliva and genital secretions. CT enhanced the VLP-specific antibody response 10-fold in serum and to a lesser extent in saliva and genital secretions. Nasal immunization of conscious mice compared to anesthetized mice was inefficient and correlated with the absence of uptake of a marker into the lung. However, a 1-μg VLP systemic priming followed by two 5-μg VLP intranasal boosts in conscious mice induced both HPV16 VLP-specific IgG and IgA in secretions, although the titers were lower than in anesthetized mice given three intranasal immunizations. Antibodies in serum, saliva, and genital secretions of immunized mice were strongly neutralizing in vitro (50% neutralization with ELISA titers of 65 to 125). The mucosal and systemic/mucosal HPV16 VLP immunization protocols that induced significant titers of neutralizing IgG and secretory IgA in mucosal secretions in mice may be relevant to genital HPV VLP-based human vaccine trials.Keywords
This publication has 64 references indexed in Scilit:
- The influence of virus structure on antibody responses and virus serotype formationImmunology Today, 1996
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI: Journal of the National Cancer Institute, 1995
- Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to miceVaccine, 1995
- Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigenVaccine, 1995
- Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human seraJournal of General Virology, 1994
- Suppression of the Immune Response by Nasal ImmunizationClinical Immunology and Immunopathology, 1994
- Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptideJournal of General Virology, 1992
- The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor.Journal of Cell Biology, 1991
- Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A.Journal of Experimental Medicine, 1988
- Effect of ingested sperm on fecundity in the rat.Journal of Experimental Medicine, 1984